🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis

RecruitingNAAges 18 Years - 65 YearsAllXijing Hospital
NCT07780929 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Psoriasis is a chronic, recurrent, inflammatory, and systemic disease mediated by immunity, induced by a combination of genetic and environmental factors. Its typical clinical manifestations are scaly erythema or plaques, which may be localized or widespread. It is non-contagious, difficult to treat, and often lifelong. The etiology of psoriasis involves multiple factors, including genetics, immunity, and environment. Through an immune response primarily mediated by T lymphocytes and jointly participated in by various immune cells, it causes hyperproliferation of keratinocytes or inflammation in joint synovial cells and chondrocytes. Psoriasis is an incurable disease; however, numerous therapeutic drugs and methods are currently available. Treatment regimens should be determined based on patient symptoms: mild psoriasis is mainly treated with topical therapies, while moderate-to-severe c

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
1. Inclusion Criteria: * Diagnosis of plaque psoriasis. * Mild-to-moderate disease presentation suitable for topical intervention (e.g., ≤2% to 10% BSA). * Provision of written informed consent prior to study procedures. 2. Exclusion Criteria: * Non-plaque subtypes (e.g., erythrodermic, pustular, or generalized guttate psoriasis). * Recent use of systemic antipsoriatic therapies, biologics, or topical steroids/retinoids within the protocol-defined washout period. * Active localized skin infection at target sites or known hypersensitivity to XJH05 or ointment ingredients.
💊

What it tests

  • XJH05 ointment
  • Calcipotriol ointment
📍

Where

1 site
Department of Dermatology, Xijing Hospital, Air Force Medical University
Xi'an, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy